Seres Therapeutics, Inc. — FY2021 Form 10-K
Reporting period: Year ended December 31, 2021. Filed March 1, 2022. Seres is a clinical-stage microbiome therapeutics company with no product sales; its lead candidate, SER-109, is in development for recurrent C. difficile infection (CDI).
Financial performance and position
Amounts below are USD millions except per-share data.
| Metric | 2021 | 2020 | Change / context |
|---|---|---|---|
| Total revenue | $144.9 | $33.2 | Up $111.7; primarily reflects Nestlé license revenue, not product sales. |
| Research and development | $141.9 | $90.6 | Up $51.3, including higher SER-109 and platform spending. |
| General and administrative | $69.3 | $30.8 | Up $38.5, including personnel, professional fees and pre-launch costs. |
| Loss from operations | $(64.5) | $(88.1) | Improved as collaboration revenue rose. |
| Net loss | $(65.6) | $(89.1) | Loss per share was $(0.72), versus $(1.12). |
| Operating cash flow | $6.7 | $(93.6) | 2021 inflow was driven largely by working-capital changes, including accrued liabilities. |
| Cash, cash equivalents and investments | $291.2 | Not stated here on a directly comparable basis | At December 31, 2021; excludes restricted cash and restricted investments. |
| Long-term debt, carrying value | $24.6 | $25.1 approximately | Year-end balance; February 2022 borrowing amendment is described below. |
No product gross margin is reported because Seres had no product sales. Current assets were $303.6 million and current liabilities $82.3 million at year-end. The company reported an accumulated deficit of $614.4 million.
Material changes and unusual items
- Revenue included $133.4 million recognized under the July 2021 Nestlé U.S./Canada SER-109 license, including $131.3 million for the license and $2.1 million for services. The $175 million upfront payment was allocated among accounting obligations; it is not all recurring revenue. Seres may receive additional regulatory and sales milestones, but these are contingent.
- R&D and G&A spending increased substantially as the company advanced SER-109 and expanded research, manufacturing and commercialization readiness. Stock-based compensation was $20.2 million, versus $8.8 million in 2020.
- Investing cash flow was positive $64.1 million, mainly because investment maturities exceeded purchases. Financing cash flow was $1.2 million; Seres did not sell shares through its ATM in 2021.
- In November 2021, Seres agreed to a long-term Bacthera manufacturing arrangement with payments of at least CHF 240 million (approximately $262 million) over its initial term, including construction and operating fees. The contractual-obligations table reports $255.7 million for this agreement.
Programs, outlook and key risks
- SER-109: The Phase 3 ECOSPOR III trial met its primary endpoint. Recurrence through eight weeks was reduced by an absolute 27 percentage points versus placebo; through 24 weeks, recurrence was 21.3% versus 47.3%. Seres reported reaching the 300-subject safety-database enrollment target in 2021. At filing, it planned to seek FDA agreement for a rolling BLA submission in the first half of 2022 and to complete it with safety follow-up data around mid-2022. FDA approval was not assured.
- SER-287: Its 203-patient Phase 2b UC study failed to improve clinical remission versus placebo (10.3% and 10.6% in active arms versus 11.6% for placebo). Seres closed the study’s open-label and maintenance portions. Bacterial engraftment occurred, but anticipated disease-relevant metabolite changes were not observed.
- SER-301: In the first 15-subject Phase 1b cohort, no subjects achieved clinical remission after 10 weeks; efficacy was not a defined endpoint for that cohort. The safety board supported proceeding to the placebo-controlled cohort. Engraftment and metabolite changes were observed, but clinical benefit remains unproven.
- SER-155: The first patient entered its Phase 1b study in November 2021. The candidate is intended to reduce infections and graft-versus-host disease in transplant recipients.
- Other pipeline: Seres discontinued further enrollment in the SER-401 melanoma study, citing enrollment challenges, COVID-19 effects and prioritization of other oncology work.
- Funding and debt: Management expected year-end liquidity plus $27.6 million of net proceeds from a February 2022 Hercules facility amendment to fund operations, debt service and capital spending for at least 12 months from issuance of the financial statements. Management also expects continuing losses and says additional financing will be needed for future operations. The amended facility provides up to $100 million in tranches; $50 million was outstanding as of February 24, 2022, with further borrowing conditional. Interest is at least 9.65%, and the facility has covenants and end-of-term charges.
- Principal risks: clinical and regulatory uncertainty for a novel drug modality; need for further capital; reliance on Nestlé, contract manufacturers and human-donor material; manufacturing scale-up and quality risks; the substantial Bacthera commitment; competition, reimbursement and market-acceptance uncertainty; and potential COVID-19-related disruption. Seres reported effective disclosure controls and internal control over financial reporting; its auditor emphasized the need for additional financing to fund future operations.
The filing provides no formal financial guidance. Its stated near-term outlook centers on pursuing SER-109 FDA review and advancing selected clinical programs; timing and outcomes depend on regulatory, clinical and manufacturing developments.
Important facts for investors to verify
- FDA feedback, BLA submission status, review timing and any additional evidence required for SER-109.
- Whether the reported SER-109 trial results and safety follow-up support approval, and the commercial launch and supply readiness of Seres and Nestlé.
- Cash burn and runway after accounting for the February 2022 borrowing, future debt service, contingent loan tranches and the Bacthera commitment.
- Next-cohort results and development plans for SER-301, and whether SER-287 biomarker analyses lead to a viable targeted strategy.
- Terms and performance obligations under the Nestlé and Bacthera agreements, including milestone conditions, commercialization economics and potential termination consequences.